Novavax initiated with a Buy at BTIG

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a user-friendly mix of high-efficacy and improved safety that, with Sanofi’s (SNY) marketing muscle, could become a “significant” player in the $9B COVID vaccine space, the analyst tells investors in a research note. The firm added that Nuvaxovid is in clinical testing with three influenza vaccines to formulate COVID influenza combination vaccines.